Elevance Health, Inc. $ELV Shares Acquired by Field & Main Bank

Field & Main Bank lifted its stake in shares of Elevance Health, Inc. (NYSE:ELV) by 2,984.0% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,542 shares of the company’s stock after buying an additional 1,492 shares during the period. Field & Main Bank’s holdings in Elevance Health were worth $498,000 at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in ELV. Janney Montgomery Scott LLC grew its stake in Elevance Health by 0.6% during the 2nd quarter. Janney Montgomery Scott LLC now owns 48,049 shares of the company’s stock valued at $18,689,000 after purchasing an additional 272 shares during the last quarter. HB Wealth Management LLC boosted its position in Elevance Health by 8.1% in the second quarter. HB Wealth Management LLC now owns 21,747 shares of the company’s stock valued at $8,459,000 after buying an additional 1,629 shares during the last quarter. Raleigh Capital Management Inc. raised its position in Elevance Health by 24.7% during the 2nd quarter. Raleigh Capital Management Inc. now owns 278 shares of the company’s stock worth $108,000 after buying an additional 55 shares during the last quarter. Trivium Point Advisory LLC lifted its stake in Elevance Health by 12.9% during the 2nd quarter. Trivium Point Advisory LLC now owns 629 shares of the company’s stock valued at $245,000 after acquiring an additional 72 shares during the period. Finally, PBMares Wealth Management LLC boosted its holdings in shares of Elevance Health by 12.6% in the 2nd quarter. PBMares Wealth Management LLC now owns 858 shares of the company’s stock valued at $334,000 after acquiring an additional 96 shares during the last quarter. 89.24% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have weighed in on ELV. TD Cowen reaffirmed a “buy” rating on shares of Elevance Health in a research report on Wednesday, November 26th. Robert W. Baird raised their price objective on shares of Elevance Health from $297.00 to $340.00 and gave the stock a “neutral” rating in a research note on Thursday, December 11th. Truist Financial set a $400.00 target price on shares of Elevance Health in a research note on Tuesday, October 14th. Wall Street Zen cut shares of Elevance Health from a “buy” rating to a “hold” rating in a report on Saturday, December 13th. Finally, Guggenheim raised their target price on Elevance Health from $398.00 to $414.00 and gave the company a “buy” rating in a research report on Thursday, January 22nd. Twelve equities research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $399.63.

Elevance Health News Summary

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Q4 EPS beat consensus ($3.33 vs. $3.10) and management cited rising premiums plus a surge in Carelon revenues — a key reason investors see continued earnings resilience. Elevance Health Q4 Earnings Beat
• Positive Sentiment: Board raised the quarterly dividend to $1.72 (annualized yield ~2.0%), a modest increase from $1.71 — supportive for income-focused shareholders and signals confidence in cash flow.
• Neutral Sentiment: Revenue grew ~9.6% YoY to $49.31B but came in slightly below consensus; net margin and ROE remain modest, so growth is present but profit dynamics are mixed. Press Release / Slide Deck
• Negative Sentiment: FY‑2026 EPS guidance was lowered to about 25.50, below the Street (~26.89); management warned medical costs will remain elevated, which is a direct near‑term headwind to margins and valuation. Elevance forecasts 2026 profit below estimates
• Negative Sentiment: Market commentary highlights Medicare Advantage and reimbursement/membership pressures as reasons for selloff and heightened volatility in ELV shares following the earnings release. Barron’s: Earnings adding to Medicare pain

Elevance Health Price Performance

NYSE:ELV opened at $342.01 on Thursday. The stock has a 50 day moving average of $350.56 and a two-hundred day moving average of $328.87. Elevance Health, Inc. has a 12 month low of $273.71 and a 12 month high of $458.75. The firm has a market cap of $76.01 billion, a P/E ratio of 13.98, a price-to-earnings-growth ratio of 1.66 and a beta of 0.51. The company has a current ratio of 1.56, a quick ratio of 1.56 and a debt-to-equity ratio of 0.71.

Elevance Health (NYSE:ELV) last issued its quarterly earnings results on Wednesday, January 28th. The company reported $3.33 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.10 by $0.23. Elevance Health had a return on equity of 16.17% and a net margin of 2.84%.The firm had revenue of $49.31 billion for the quarter, compared to analyst estimates of $49.52 billion. During the same period in the previous year, the company posted $3.84 earnings per share. The business’s revenue was up 9.6% on a year-over-year basis. Elevance Health has set its FY 2026 guidance at 25.500- EPS. On average, analysts expect that Elevance Health, Inc. will post 33.96 earnings per share for the current fiscal year.

Elevance Health Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, March 25th. Stockholders of record on Tuesday, March 10th will be paid a $1.72 dividend. This is an increase from Elevance Health’s previous quarterly dividend of $1.71. This represents a $6.88 annualized dividend and a dividend yield of 2.0%. The ex-dividend date of this dividend is Tuesday, March 10th. Elevance Health’s payout ratio is 27.96%.

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.